Human gC1qR (also known as p33 or p32), originally cloned as a splicing factor 2-associated protein (1) , has been reported to interact with a variety of molecules including, but not limited to, cell surface adrenergic and GABA receptors, protein kinase C, and certain viral and bacterial proteins (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In addition to these proteins, gC1qR represents a receptor of complement component 1q (C1q 1 ; the subcomponent of the C1 complex of the classical pathway of complement activation) in tumor cells and can interact with globular heads of C1q (12) (13) (14) (15) . In cells, gC1qR is present in the cytosol, the plasma membrane, and mitochondria, and the soluble forms of gC1qR are released into the surrounding milieu by proliferating cells (3, 16) . The soluble gC1qR protein inhibits C1q hemolytic activity (3, 16) . Once released by cells, soluble gC1qR may play important roles in vivo as regulator of complement activation. In this manner, proliferating cells may evade destruction or elimination by complement.
Recently, a membrane-tethered membrane type 1 matrix metalloproteinase (MT1-MMP) (17) , an enzyme shown to be essential to tumor invasion and metastasis (18 -20) , has been found to associate with gC1qR via the enzyme's cytoplasmic tail.
2 MT1-MMP is largely localized to the invasive front of highly motile cancer cells (21) (22) (23) . This protease is thought to be directly involved in matrix breakdown (24) and proteolysis of cell surface receptors (25) (26) (27) . Although a direct functional link between gC1qR and MT1-MMP is still uncertain, our observations suggested that there might be reciprocal interactions involving these proteins in vivo. This prompted us to evaluate whether gC1qR is susceptible to MT1-MMP proteolysis.
Here, we report that breast carcinoma cells release soluble gC1qR in the medium. MT1-MMP forms an enzyme-substrate complex with released gC1qR and cleaves this protein in vitro and in cell culture conditions. Our findings imply that the proteolytically inactive full-length MT1-MMP species may represent cell surface receptors of gC1qR, while MT1-MMP activity expressed at the surface of aggressive tumor cells is likely to reduce the levels of soluble gC1qR in the tumor vicinity.
MATERIALS AND METHODS
Antibodies and Reagents-A murine mAb 60.11, directed against the N-terminal portion of gC1qR, and rabbit polyclonal antibody pAB-p33 were described earlier (12, 28) . Where indicated, mAb 60.11 was labeled with sulfo-N-hydroxysuccinimide-LC-biotin (Pierce) and separated from excess biotin according to the manufacturer's recommendations. Rabbit antibody AB815 against a 285-318 hinge region of MT1-MMP was from Chemicon International (Temecula, CA). Goat anti-rabbit IgG conjugated with horseradish peroxidase (HRP); donkey anti-mouse IgG conjugated with HRP; and soluble Ser 24 -Val 524 pro-MT1-MMP consisting of the prodomain, the catalytic (CAT) domain and the hemopexinlike (PEX) domain (pro-MT1-MMP-PEX) were from Chemicon. fied, and refolded as described earlier (29) . Polyclonal antibody against MT1-MMP-CAT was raised in rabbits and affinity-purified on immobilized MT1-MMP-CAT from immune serum in our laboratory. Control rabbit and murine IgG and phorbol 12-myristate 13-acetate (PMA) were from Sigma. Recombinant gC1qR was purified and refolded from E. coli as described (28) . Pro-MMP-2, essentially free from TIMP-2, was isolated from medium conditioned by p2AHT2A72 cells (a derivative of the HT1080 fibrosarcoma cell line doubly transfected with E1A and pro-MMP-2) (30, 31) . Human TIMP-1 and TIMP-2 were from Fuji Chemical Industries (Tokyo, Japan). Glucose oxidase from Aspergillus niger was obtained from Sigma. A hydroxamate class inhibitor of MMP activity, GM6001 (32) , was from AMS Scientific (Concord, CA). The hydroxamate inhibitor AG3340 (33) was kindly provided by P. Baciu (Allergan Pharmaceuticals, Inc., Irvine, CA).
MT1-MMP Constructs and Cell Transfection-Breast carcinoma parental MCF7 cells and the MCF7 stably transfected cell lines expressing the full-length human wild type MT1-MMP (MT1-MMP-WT; GenBank TM accession number U41078), the catalytically inactive MT1-MMP mutant (MT1-MMP-E240A) in which Ala 240 replaced the essential Glu 240 residue of the enzyme's active site (34) , and the cytoplasmic tail-truncated MT1-MMP mutant (MT1-MMP-⌬CT) were described earlier. 2 The transfected cell pools of 3-6 respective positive clones were used in our studies to avoid any clone-specific effects. Mock cells transfected with the original pcDNA3-zeo plasmid were generated as a pool of zeocin-resistant cells. Transfected cells were routinely grown in Dulbecco's modified Eagle's medium plus 10% fetal calf serum and 0.2 mg/ml zeocin.
Human fibrosarcoma HT1080 cells naturally expressing MT1-MMP and pro-MMP-2 were obtained from the ATCC (Manassas, VA). Where indicated, cells were stimulated with 50 ng/ml PMA to induce MT1-MMP activity and pro-MMP-2 activation.
Immunoprecipitation-Cells were surface-biotinylated for 1 h with 0.1 mg/ml sulfo-N-hydroxysuccinimide-LC-biotin. Labeled cells were solubilized at 5 ϫ 10 6 to 1 ϫ 10 7 cells/ml in Tris-buffered saline, pH 7.4, containing 50 mM n-octyl-␤-D-glucopyranoside, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, 1 g/ml leupeptin, 1 g/ml pepstatin, and 1 g/ml aprotinin for 1 h on ice. Insoluble material was removed by centrifugation. Supernatants were precleared for 2 h on ice with Protein A-agarose beads (Calbiochem). Aliquots (1 mg of total protein) of precleared supernatants were incubated overnight at 4°C with 1-3 g of anti-MT1-MMP AB815 or anti-gC1qR antibody pAB-p33 and 30 l of a 50% Protein A-agarose slurry. Following washing, the beads were boiled with 2ϫ SDS sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 0.005% bromphenol blue, and 20% glycerol) with 50 mM dithiothreitol for 5 min. Eluted proteins were separated by SDS-PAGE and transferred onto an Immobilon-P membrane (Millipore Corp., Bedford, MA). Bands containing biotin-labeled proteins were visualized by using ExtrAvidin-HRP (Sigma) and the TMB/M substrate (Chemicon).
Proteolysis of gC1qR by MT1-MMP-To generate catalytically active MT1-MMP-PEX, 600 ng of soluble Ser 24 -Val 524 pro-MT1-MMP-PEX (12 pmol) was activated by incubating with 30 ng of MT1-MMP-CAT (1.5 pmol; 1:8 molar ratio) for 1 h at ambient temperature. 100-ng aliquots of MT1-MMP-PEX (2 pmol) were immediately used to cleave 2 g of gC1qR (60 pmol) for 0.5-4 h at 37°C in 20 l of 50 mM HEPES, 10 mM CaCl 2 , 50 M ZnCl 2 , 0.01% Brij buffer, pH 6.8. In addition, gC1qR (2 g, 60 pmol) was treated with MT1-MMP-CAT (50 ng, 2 pmol) for 0.5-4 h in the same buffer.
The cleavage reactions were stopped by adding 2ϫ SDS sample buffer. The cleavage products were separated by SDS-PAGE and analyzed by Western blotting employing anti-gC1qR mAb 60.11. The main cleavage product, with an apparent molecular mass of 17 kDa, was subjected to N-terminal protein microsequencing.
Activation of Pro-MMP-2 by MT1-MMP-CAT-Aliquots (200 ng) of pro-MMP-2 essentially free from TIMP-2 were activated by MT1-MMP-CAT (20 ng) for 1.5 h at 37°C in 50 mM HEPES, pH 6.8, containing 10 mM CaCl 2 , 50 M ZnCl 2 , and 0.01% Brij-35. Gelatin zymography (35) was used to verify the conversion of the 68-kDa pro-MMP-2 into the 62-kDa activated MMP-2 enzyme. Further, the purified gC1qR (2 g) was incubated with activated MMP-2 (100 ng) for 6 h followed by SDS-PAGE of the digested samples.
Digestion of ELISA-ELISA was used to quantify biotin-labeled gC1qR. The gC1qR protein was labeled with sulfo-N-hydroxysuccinimide-LC-biotin according to the manufacturer's recommendations (Pierce). Wells of a 96-well plate (Costar, Cambridge, MA) were coated with anti-gC1qR mAb 60.11 (1 g/ml) in PBS at 4°C overnight. After removing unbound antibody, wells were blocked with 1% casein in PBS for 1 h at 37°C. Medium samples (100 l) were allowed to bind immobilized mAb 60.11 for 1 h at 37°C. After washing, bound biotin-labeled material was identified by ExtrAvidin-HRP and the TMB/E substrate. The A 450 of the samples was measured in a microplate reader. The concentrations of gC1qR in the medium samples were calculated by using a calibration curve that ranged from 10 to 100 ng/ml. Washes between reactions were done in PBS containing 0.1% Tween 20.
Binding of gC1qR with MT1-MMP-CAT and MT1-MMP-PEX-Wells of a 96-well plate (Costar) were coated overnight at 4°C with 100 l of PBS containing MT1-MMP-CAT (200 ng/ml) or MT1-MMP-PEX (500 ng/ml; an equimolar amount relative to that of MT1-MMP-CAT). After blocking with 1% casein in PBS, MT1-MMP-CAT or MT1-MMP-PEX was incubated for 1 h at 37°C in 100 l of PBS supplemented with AGN3340 (1 M), GM6001 (1 M), TIMP-2 (2 g/ml), or TIMP-1 (2 g/ml) or left untreated. Afterward, gC1qR solution (10 g/ml) in 1% casein-PBS was allowed to bind the MT1-MMP samples for 1 h at 37°C. Bound gC1qR was detected by incubating the plate with mAb 60.11 (1 g/ml in PBS-1% casein) followed by incubation with donkey antimouse IgG conjugated with HRP and the TMB/E substrate. The plate was washed with PBS containing 0.1% Tween 20 between each change of reagents. The reading of casein control (background) was subtracted from the A 450 values of the experimental samples.
Determination of Protein Concentration-Protein concentration was determined by dye methods with a Bio-Rad assay kit with bovine serum albumin as the standard.
RESULTS
gC1qR Cleavage by MT1-MMP in Vitro-Two soluble truncated forms of MT1-MMP, specifically pro-MT1-MMP-PEX, comprising both the CAT domain and the PEX domain, and the MT1-MMP-CAT construct that represents the individual catalytic domain of the enzyme, were used in our studies. The MT1-MMP-CAT construct isolated from E. coli exhibits high proteolytic activity after refolding (29) . Activation is required to convert the pro-MT1-MMP-PEX latent zymogen into the catalytically active MT1-MMP-PEX enzyme. The pro part of MT1-MMP-PEX was cleaved by MT1-MMP-CAT to generate catalytically active MT1-MMP-PEX. MT1-MMP-PEX was immediately used in the gC1qR cleavage reactions. At the 1:30 enzyme-substrate molar ratio, proteolytically active MT1-MMP-PEX (2 pmol) cleaved gC1qR (60 pmol), generating the predominant proteolytic fragment with a molecular mass of about 17 kDa and two minor fragments, 12 and 11 kDa (Fig. 1A) .
Since glucose oxidase has an acidic pI value similar to that of gC1qR, this control protein was used in our studies. In a 5-fold molar excess relative to gC1qR, glucose oxidase failed to affect the gC1qR proteolysis, thus supporting the unique sensitivity of gC1qR to MT1-MMP-PEX (Fig. 1B) . Both GM6001 (1 M), a wide range hydroxamate inhibitor of MMPs, and TIMP-2 (200 ng, 10 pmol) fully inhibited the cleavage of gC1qR by MT1-MMP-PEX. In contrast, TIMP-1 (270 ng, 9 pmol), known as a poor inhibitor of MT1-MMP (36), had no effect (Fig. 1B) . Earlier, we found that the cytoplasmic tail sequence of MT1-MMP associates with gC1qR. 2 Our present observations show that, apparently, there is a second gC1qR binding site in the MT1-MMP molecule. We suggest that this site comprises the enzyme's CAT domain involved in the enzyme-substrate MT1-MMP⅐gC1qR complex.
Intriguingly, the individual MT1-MMP-CAT construct that lacks the PEX domain in contrast to MT1-MMP-PEX was incapable of cleaving gC1qR (Fig. 1C) . Evidently, the presence of the PEX domain is critical to accomplishing the cleavage of gC1qR by the protease.
Further, we examined whether MMP-2 is capable of cleaving gC1qR (Fig. 2) . For these purposes, pro-MMP-2 essentially free of TIMP-2 was isolated from medium conditioned by p2AHT2A72 cells (a derivative of the HT1080 fibrosarcoma cell line doubly transfected with E1A and pro-MMP-2) (30, 31). Purified MMP-2 was activated by MT1-MMP-CAT. The conversion of the 68-kDa latent zymogen into the 62-kDa enzyme of MMP-2 was confirmed by gelatin zymography (Fig. 2A) . The activated MMP-2 enzyme was immediately employed in our cleavage studies. However, as can be seen in Fig. 2B , activated MMP-2 failed to induce any significant hydrolysis of gC1qR.
The Cleavage Site Sequence-To identify relative positions of the cleavage fragments within the gC1qR molecule, we used Western blotting with mAb 60.11 directed to the N-terminal portion of gC1qR. This antibody recognized the 12-and 11-kDa cleavage fragments but failed to interact with the 17-kDa fragment of gC1qR (Fig. 3) . These data indicated that the MT1-MMP cleavage sites were located within the N-terminal part of the gC1qR molecule. The N-terminal sequencing of the 17-kDa fragment indicated that MT1-MMP cleaved the mature gC1qR protein at the PSQG 79 2 80 QKVE site, providing the 17-kDa fragment with the N-terminal QKVEEQE sequence. In the known crystal structure of the doughnut-shaped gC1qR (5), the PSQG 79 Q 80 KVE segment represents a highly disordered 68 PT-FDGEEEPSQGQKVEEQEPE 88 part of the loop connecting the ␤ 3 strand to the ␤ 4 strand (Fig. 3B) . The surface location of this structurally disordered loop explains its sensitivity to proteolysis. Evidently, the binding of the loop sequence to the PEX domain is necessary to achieve the proper orientation of the loop relative to the active site of MT1-MMP-PEX. This may explain the inability of MT1-MMP-CAT that lacks the PEX sequence to accomplish the cleavage of qC1qR. The subsequent computer modeling supports this hypothesis (see "Discussion").
Cleavage of gC1qR in Cell Cultures-The in vitro results prompted us to examine whether gC1qR is sensitive to MT1-MMP expressed in MCF7 breast carcinoma cells. We specifically selected this cell line for our studies, since it is deficient in pro-MMP-2 and MT1-MMP (34, 37) . This provided us with the opportunity to specifically identify the effects of MT1-MMP expressed in stably transfected cells.
First, we evaluated by Western blotting the levels of soluble gC1qR in medium conditioned by mock cells and by cells expressing the MT1-MMP-E240A, MT1-MMP-WT, and MT1-MMP-⌬CT constructs. All cell lines exhibited soluble gC1qR in medium. We found that there was no significant difference in the levels of soluble natural gC1qR (about 10 -20 ng/ml) in these cell lines (Fig. 4A) .
Second, we evaluated the ability of cellular MT1-MMP to degrade soluble gC1qR. To eliminate the contribution of the biosynthesis of gC1qR and to specifically target the degradation of this protein, we used biotin-labeled gC1qR. For these purposes, 30 ng/ml biotin-labeled gC1qR was added to medium conditioned by mock cells and by cells expressing the MT1-MMP-E240A, MT1-MMP-WT, and MT1-MMP-⌬CT constructs. After incubation of biotin-gC1qR with cells for 16 h, the residual concentrations of biotin-gC1qR in medium were measured by ELISA and calculated by using a calibration curve (Fig. 4B) , which ranged from 10 to 100 ng/ml biotin-labeled gC1qR (Fig.  4B, inset) . The levels of biotin-gC1qR remained largely unchanged in medium conditioned by the cell lines expressing no MT1-MMP activity such as mock cells and MT1-MMP-E240A-transfected cells. In turn, cell lines expressing MT1-MMP activity such as MT1-MMP-WT and MT1-MMP-⌬CT cells were both competent in depleting biotin-gC1qR (Fig. 4C) . Thus, there was a correlation between expression of functionally active MT1-MMP in the cells and the levels of soluble gC1qR in the medium, thereby suggesting the degradation of gC1qR by this protease. Importantly, biotinylation did not significantly alter sensitivity of gC1qR to the cleavage by MT1-MMP-PEX (data not shown).
The contribution of MT1-MMP to proteolysis of gC1qR was further confirmed by employing HT1080 fibrosarcoma cells in our studies. This cell line is known to express endogenous MT1-MMP, which upon stimulation for example by phorbol esters is recruited to the plasma membrane (31, 38, 39) . At the cell surface, MT1-MMP participates in pro-MMP-2 activation (30, 40) . This inducible expression allowed us to examine how cell surface MT1-MMP contributes to the proteolysis of gC1qR (Fig. 4C, inset) . For these purposes, biotin-labeled gC1qR was added to medium conditioned by PMA-stimulated or untreated HT1080 cells. Pretreatment of HT1080 cells with PMA resulted in efficient activation of pro-MMP-2, while less significant activation of pro-MMP-2 was observed in untreated cells (Fig. 4C,  inset) . Concomitantly, PMA pretreatment enhanced degradation of biotin-labeled gC1qR by HT1080 cells and, accordingly, decreased the levels of the labeled protein in the medium. The addition of the hydroxamate GM6001 inhibitor alone or its co-addition with PMA strongly inhibited both the proteolysis of gC1qR and activation of MMP-2 in HT1080 cells (Fig. 4C) . Since purified activated MMP-2 failed to cleave gC1qR (Fig. 2) , our data suggest that MT1-MMP naturally expressed in HT1080 cells is directly involved in proteolysis of gC1qR. 
gC1qR in Vitro Binds the Catalytic Domain of MT1-MMP-
Next, we examined the ability of MT1-MMP-CAT and MT1-MMP-PEX to directly bind gC1qR. For these purposes, the purified and refolded MT1-MMP-CAT or MT1-MMP-PEX were each coated on plastic and then allowed to bind gC1qR in the presence and absence of MT1-MMP inhibitors including hydroxamate class inhibitors AGN3340 and GM6001 and TIMPs such as TIMP-1 (a poor inhibitor of MT1-MMP activity) and TIMP-2 (a potent inhibitor of MT1-MMP activity). After washings, the bound gC1qR was identified by mAb 60.11 followed by incubation of immune complexes with an HRP-conjugated secondary antibody. Our data indicated that MT1-MMP-CAT was capable of directly associating with gC1qR. Inhibition of MT1-MMP activity reduced but not abolished the ability of the recombinant construct to bind gC1qR. Similarly to MT1-MMP-CAT, MT1-MMP-PEX was capable of binding to gC1qR, and the binding was sensitive to inhibition by a hydroxamate (Fig. 5A) .
The cleavage of ␣ 1 -antitrypsin by MT1-MMP was used to confirm the proteolytic activity of the MT1-MMP-CAT construct and the effects caused by the inhibitors. Consistent with the observations of other authors (41, 42) , ␣ 1 -antitrypsin was sensitive to MT1-MMP. Thus, at the about 1:15 enzyme-substrate ratio, MT1-MMP-CAT (20 ng) efficiently cleaved ␣ 1 -antitrypsin (1 g) (Fig. 5B) . All three potent inhibitors of MT-MMP activity (AGN3340, GM6001, and TIMP-2) fully blocked the gC1qR proteolysis by MT1-MMP-CAT, while TIMP-1 failed to significantly affect MT1-MMP activity. These findings presumably indicate that there is a partial but not complete overlap of the gC1qR-and inhibitor-binding sites within the active site of the catalytic domain of MT1-MMP. Particularly, these data suggest that once inhibited by hydroxamates or TIMP-2, MT1-MMP expressed at the plasma membrane may represent a cellular receptor of gC1qR.
gC1qR Binds with Hydroxamate-inactivated MT1-MMP in the Cell System-To confirm our in vitro observations, we employed cells expressing MT1-MMP-WT in biotinylation and immunoprecipitation studies. A sensitive procedure for surface biotinylation and immunoprecipitation provided data about cell surface expression of MT1-MMP. Several major forms of MT1-MMP have been described in cells, including a 63-kDa zymogen, an active species at 55-60 kDa, and the catalytically inactive truncated fragments of 38 -45 kDa (34, 43) . In agreement, anti-MT1-MMP antibody precipitated the full-length MT1-MMP and its degradation fragments from lysates of surface-biotinylated cells preincubated with or without GM6001, respectively (Fig. 6) . No specific bands were observed in mock cells.
Anti-gC1qR pAB-p33 precipitated a 33-kDa biotin-labeled protein from the lysates of MT1-MMP-WT cells pretreated with GM6001. This band was highly similar in its mobility to the purified biotin-labeled gC1qR control. No similar bands were observed in mock cells and untreated MT1-MMP-WT cells. Remarkably, the material precipitated with anti-MT1-MMP antibody demonstrated the presence of the same 33-kDa protein in cells pretreated with GM6001, while no co-precipitation of this protein with MT1-MMP was observed in untreated cells (Fig. 6) . Conversely, a band that resembled the catalytically inactive truncated fragment of MT1-MMP was co-immunoprecipitated with gC1qR. Similar results were obtained with another potent hydroxamate inhibitor AGN3340 (data not shown).
Computer 1 M) , TIMP-1, or TIMP-2 (both at 2 g/ml) were added to the reaction. The digests were analyzed by SDS-PAGE, and the gels were stained with Coomassie.
protein, which is presumably associated with the mechanisms of trafficking and internalization of the protease (62) . gC1qR exhibits many puzzling features, and its functional role is not understood in detail (3). gC1qR exists in two molecular forms, the 1-282 precursor and the 74 -282 mature protein. The mature gC1qR is generated by post-transcriptional proteolytic processing, whose mechanisms are unknown. Since the N-terminal region of premature gC1qR has a structure typical to mitochondrial signal peptide, the gC1qR precursor is directed to the mitochondrial matrix, where it is thought to be important for the maintenance of mitochondrial oxidative phosphorylation (54, 55) . The mature multiligand-binding gC1qR protein participates in many interactions outside mitochondria and may be found at the cell membrane, in the cytosol, in the nucleus, and in the extracellular milieu (3, 16) . The gC1qR protein was shown to directly regulate the functional activity of the splicing factor SF2/ASF (1), protein kinase C (11), adrenergic receptor (10), GABA receptor ␤ subunit (9), the plasma complement component C1q (12, 15) , high molecular weight kininogen (56) , factor XII (6), and some other plasma and extracellular matrix proteins. In addition, mature gC1qR is believed to interact with certain viral proteins (57, 58) and be involved in their trafficking to the nucleus. Once released by cells into the extracellular milieu, the soluble gC1qR protein may inhibit C1q hemolytic activity (16) . This function of soluble gC1qR may play important roles in vivo in assisting proliferating tumor cells to evade destruction by complement.
Our current data indicate that soluble gC1qR is released by MCF7 breast carcinoma cells. Both in vitro and in cell cultures, MT1-MMP is capable of cleaving soluble gC1qR. The sequencing data show that MT1-MMP cleaved gC1qR at the PSQG 79 2 80 QKVE site, providing the 17-kDa fragment with the N-terminal QKVEEQE sequence. In the known crystal structure of the doughnut-shaped gC1qR, the PSQG 79 Q 80 KVE segment represents a part of a highly disordered loop connecting the ␤ 3 strand to the ␤ 4 strand (5). The PSQG 79 2 80 QKVE cleavage sequence is distantly similar to the PX(P/G)L consensus cleavage site of MT1-MMP elucidated by using phage display libraries (59) . The surface location of this loop may explain its high sensitivity to proteolysis by MT1-MMP.
Another MMP, the soluble MMP-2 enzyme, which is functionally associated with MT1-MMP and known to be activated by MT1-MMP (17), failed to accomplish cleavage of gC1qR. Since the individual catalytic domain (MT1-MMP-CAT) is void of the gC1qR-cleaving activity, the presence of the PEX domain in the MT1-MMP construct is essential to the efficient cleavage of gC1qR. Earlier, the PEX domain of several MMPs has been shown to play a critical functional role in substrate binding and/or in interactions with TIMPs (51) . Clearly, the PEX domain plays a crucial role in recognition of gC1qR by MT1-MMP.
Our computer studies showed that in the MT1-MMP⅐gC1qR complex, both the PEX domain and the CAT domain of the protease are definitely involved in the interactions with gC1qR. This computer modeling supports our experimental cleavage data and demonstrates that the PEX domain is likely to strongly affect the mechanisms involved in the binding and proteolysis of gC1qR by MT1-MMP.
Our data suggest that both MT1-MMP in the cells naturally expressing the enzyme and MT1-MMP exhibited by the transfected cells hydrolyze soluble gC1qR existing in medium. This may modulate the levels of gC1qR in the tumor cell microenvironment. To our knowledge, this is the first evidence that cellular MT1-MMP is capable of cleaving a soluble, nonmatrix protein. Remarkably, inhibition of cell surface MT1-MMP activity by hydroxamate inhibitors promoted co-precipitation of the protease with the soluble gC1qR protein from the extracellular milieu. These observations suggest that inhibition of MT1-MMP activity is likely to convert the protease into a cell surface receptor of gC1qR and, subsequently, C1q. The calculations based on our immunoprecipitation studies suggest that MT1-MMP-WT cells preincubated with hydroxamate inhibitor GM6001 are able to manifest hundreds of the gC1qR molecules per cell. It is tempting to hypothesize that inhibition of MT1-MMP by hydroxamates and the subsequent complex formation of the inhibited MT1-MMP molecules with gC1qR may promote an immune-mediated attack on those target cells in vivo (60, 61) . This may superficially contribute to invasion of tumor cells, which have escaped inhibitor and still expressed functionally active MT1-MMP. Experiments are currently under way to determine whether the MT1-MMP⅐gC1qR complex represented by the hydroxamate-treated cells can be a designated receptor for C1q and to facilitate selective elimination of tumor cells by the immune system. Our data support the emerging concept that an integration of matrix degradation and limited proteolysis of both soluble and cellular key regulatory proteins influences the fate of tumor cells and their abilities to invade and metastasize. -PEX (MMP-2) chimera. The arrow points to the catalytic Zn 2ϩ ion (yellow) of the active site. The MT1-MMP cleavage site (PSQG 79 2 80 QKVE) is localized in the disordered loop that connects the ␤ 3 strand to the ␤ 4 strand of the gC1qR molecule. Since its structure is unknown (5), the loop is not depicted in our model.
